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METHOD FOR MODULATING ECOSANOID
MEDIATED IMMUNE RESPONSES IN
ARTHROPODS

This is a file-wrapper continuation of application Ser. No.

5

08/371,471 filed on Dec. 19, 1994, now abandoned which is

a file wrapper continuation of application Ser. No. 08/133,
555, filed Oct. 7, 1993, abandoned, which is a continuation

of application Ser. No. 07/825,671, filed Jan. 30, 1992,

nature and in the commercial farms.

abandoned.

Like Vertebrate Species, the immune System of inverte
brates plays a central role in the resistance of the organisms

BACKGROUND OF THE INVENTION

Invertebrates comprise 95% of all known species in the
animal kingdom and include a vast diversity of animals from
unicellular protozoans to the more complex echinoderms
and protocordates. Many Species of invertebrates are pests,
especially the 750,000 known species of insects which
compete with man for agricultural, forestal and animal
products. Other invertebrate Species act as Vectors of dis
easeS Such as malaria and trypanoSomiasis which affect
more than one billion people. In contrast, Some invertebrate
Species Serve as food Sources, Such as mollusks and
crustaceans, and are of commercial importance and, in Some
cases, commercially farmed. Thus, management of inverte
brate Species is important because of the impact of agricul
ture pests on the availability of food and other resources, the
impact of Vector born disease on human health, and the
impact of disastrous outbreaks of disease in invertebrates of
commercial importance.
One management Strategy for control of invertebrate
vectors of human or animal disease or agricultural pests
involves the use of chemical pesticides. However, many pest
Species have never been Successfully controlled with chemi
cal pesticides. Moreover, Some of the most effective chemi
cal pesticides, like DDT, have been banned from use because
of environmental and health concerns. Those pest Species
which have been successfully controlled or eradicated with
chemical pesticides can become resistant to the chemical
pesticides, necessitating the development of new chemical
formulations. Although, chemical pesticides are still widely
used, the problems of environmental contamination, risk to
human health, and resistance represent Serious drawbacks to
relying Solely on chemicals in the management of inverte
brate pests.
The current management Strategy of invertebrate pests
involves integration of Several different approaches includ
ing the use of biological control agents with or without the
use of chemical pesticides. The biological control agents
currently in use are either pathogens, parasites or predators

to disease, however, little is known about invertebrate
15
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ment have led to an increase in fatal disease outbreaks.

Unfavorable conditions include pollution of water and soils,

immune systems. It is known that invertebrates have both
cellular and humoral components that can act in a coordi
nated way to provide protection from invading pathogens.
Cellular responses mediated by hemocytes include
phagocytosis, encapsulation, and various cytotoxic reactions
Such as release of lysozyme and activation of the prophenol
oxidase System. These cellular responses are complimented
by anti-bacterial action of lysozyme and anti-bacterial pep
tides known as the cecropins, attacins, diptericins and insect
defensins. However, little is known about the early steps of
the immune response as, for example, the transduction of
foreign body invasion signals and Subsequent initiation of
early physiological defense responses. These early Steps can
be important in the eventual outcome of the infection, for
example, an early immune response may prevent significant
multiplication of a bacterial pathogen thereby preventing or
delaying death of the host invertebrate.
Therefore it is an object of the present invention to
identify Steps in the invertebrate immune response, includ
ing early steps. It is also an object of the invention to develop
compositions which can inhibit or Stimulate the immune
response in invertebrates. It is a further object of the
invention to provide biopesticide compositions and methods
of using these biopesticides to control growth of Vectors of
human disease and agricultural invertebrate pests. It is also
an object of the invention to provide therapeutic composi
tions and methods of using therapeutic compositions to
prevent fatal infections of invertebrate Species of commer
cial value.
SUMMARY OF THE INVENTION

45
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(mostly larvivorous fish). A biological control agent used

successfully is Bacillus thurigiensis which provides a toxin
used to control growth of mosquitos, black flies, Spruce bud
Worm, gypsy moth and lepidopterous pests. However, use of
Bacillus thurigiensis and other infectious agents as pesti
cides represent less than 1% of the pesticide market. Bio
logical pesticides have Several drawbacks including higher
cost, limited host range, low virulence, Short shelf life, and
difficulty in transportation. A better understanding of inver
tebrate immune defense mechanisms may contribute to
optimal utilization of available biological pesticides and to
the development of new biological control agents.
Management of commercially valuable invertebrate Spe
cies is becoming more important as unfavorable conditions
in aquacultures, commercial farms and the natural environ

2
crowded conditions that promote fighting and cannibalism
and immobilization or capture of organisms which cause
wounds. Commercial Species of importance held in crowded
conditions, like annelids, oysters, lobsters, penaeid shrimp,
and soft-shelled crabs, can be decimated by infection with
Viruses, bacteria or fungi. Attempts to prevent these infec
tions have not been described and an investigation of the
immune response of these invertebrate Species is essential to
developing a strategy to prevent loSS of these species both in

55
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These and other goals are achieved by the present inven
tion which is directed to a pharmaceutical composition
which alters the health of invertebrate organisms by affect
ing the eicosanoid-mediated immune responses, and a
method of using the composition. The pharmaceutical com
position can be used in the treatment of invertebrates to
enhance or to inhibit immunological responses. The inven
tion also provides for a biopesticide composition and
method of using the biopesticide to control or eradicate
invertebrate pests. Methods are provided for determining
which biologically active agents and what amounts are
useful in the composition.
The pharmaceutical composition is an admixture of an
effective immunoregulatory amount of at least one biologi
cally active agent which modulates invertebrate eicosanoid
mediated immune responses and a physiological acceptable
or biocompatible carrier. The biologically active agent can
act to inhibit or enhance eicosanoid-mediated immune

65

responses. An effective immunoregulatory amount is that
amount of the biologically active agent which results in a
change in the immune response. Agents which inhibit inver
tebrate eicosanoid biological activity can provide for an

6,099,834
4
Signal transduction molecules, and genes encoding peptides
which block the active site of the enzymes of the eicosanoid
biosynthetic pathway. In a preferred version, a pathogenic

3
increase in Susceptibility to disease and for an increase in
mortality of the invertebrate species. Agents which enhance
or Stimulate invertebrate eicosanoid biological activity can
provide for a decrease in Susceptibility to disease and a
decrease in mortality of the invertebrate Species. The bio
logically active agent can also be one which acts primarily
to modulate eicosanoid immune response without modifying
or altering other invertebrate biological functions like repro
ductive function or water transport functions.
The invention provides for a method to determine whether
and what amounts of the biologically active agent is effec
tive to modulate eicosanoid-mediated immune responses in
invertebrates useful in the pharmaceutical composition of
the invention. An amount of the biologically active agent
which modulates eicosanoid biosynthesis in a carrier is
administered to an invertebrate Species to yield a test popu
lation. The control population of the invertebrate Species
receives the carrier alone. Both the control and test popu
lations are inoculated with an infectious agent and incubated
for a sufficient time to allow for growth of the infectious
agent. After incubation, tissue Samples are withdrawn from
test and control groups and plated on effective growth
medium to provide for growth of infectious agent. The
amount of the infectious agent recovered from the test
population is compared to that of the control population. An
increase or decrease in the amount of the infectious agent
recovered from tissues from the test population in compari

bacteria like Serratia marceScens, is transformed with a

15

cies. The carrier can also be a food Source for the inverte
25

Son with the amount recovered from the control tissue

indicates whether and what amounts of biologically active
agent administered to the invertebrate results in a change in
the immune response.
Agents which can inhibit invertebrate eicosanoid
mediated immune responses can include antagonists of
prostaglandins, leukotrienes and arachidonic acid, inhibitors
of the enzymes of eicosanoid biosynthetic pathways, altered
intermediates and/or altered enzymes of eicosanoid biosyn
thetic pathways, and inhibitors of Signal molecules which
turn on eicosanoid biosynthesis. Preferably, the biologically
active agent is an inhibitor of the enzymes of the eicosanoid
biosynthetic pathway, and more preferably the inhibitor is a
peptide which blocks the active site of an enzyme in the
eicosanoid biosynthetic pathway.
Agents which can enhance or Stimulate invertebrate
eicosanoid-mediated immune responses include
prostaglandins, leukotrienes, arachidonic acid and analogs
thereof, agents which Stimulate the enzymes of eicosanoid
biosynthetic pathways, altered enzymes of the eicosanoid
biosynthetic pathway, inhibitors of inactivating enzymes
like dehydrogenases and reductases, and agents which
Stimulate Signal molecules which turn on eicosanoid bio
Synthesis. Preferably, the biologically active agent is an
analog of a prostaglandin, leukotriene, or arachidonic acid
and more preferably, an analog which is orally active, has
prolonged duration of biological activity and increased
potency when compared to naturally occurring eicosanoids.
The biologically active agent can also be a genetically
engineered organism which, expresses, Secretes and delivers
an agent which alters eicosanoid-mediated immune
responses. Suitable organisms can be genetically-engineered
yeast, bacteria, Viruses, plants or fungi. The organism is
preferably a microorganism which can infect and grow in the
particular invertebrate Species and, more preferably, a patho
genic microorganism. Genes can be cloned and introduced
into the organism by standard recombinant DNA methods
and include genes encoding the enzymes of the eicosanoid
biosynthetic pathway, genes encoding altered enzymes of
the eicosanoid biosynthetic pathway, genes encoding altered

plasmid containing a gene encoding a peptide which blockS
or inhibits the active site of an enzyme of the eicosanoid
biosynthetic pathway So that the pathogen expresses,
Secretes and delivers the peptide inhibitor to the target
invertebrate Species.
The biologically active agent is combined with a Suitable
carrier which functions to assist delivery of the agent to the
appropriate Site. The choice of carrier depends upon the
habitat of the invertebrate, type of food consumed by the
invertebrate, and the physical characteristics of the biologi
cally active agent. The biologically active agent is Substan
tially soluble or dispersible in the carrier and the carrier is
physiologically acceptable or compatible with invertebrates,
plants, fish and other vertebrate organisms. The carrier can
function to help the biologically active agent adhere to plant
leaves and other food Sources consumed by the target
invertebrate Species. The carrier can also function to allow
the biologically active agent to adhere and/or penetrate to
the external skeletons, shells or cuticle of invertebrate Spe

35
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brate Species. The carrier can be formulated into a liquid or
powdered mixture for Spray delivery, or as granules or
liposomes. The carrier of the composition may further be
comprised of a Surface-active agent. The Surface-active
agent readily disperses in the carrier and increases the
adherence and/or penetration of the carrier and biologically
active agent to a target site.
The invention also provides for a biopesticide composi
tion comprised of an effective pesticidal amount of at least
one biologically active agent which inhibits eicosanoid
mediated immune responses of an invertebrate organism and
a physiological acceptable carrier. An effective pesticidal
amount is that amount of the biologically active agent which
inhibits eicosanoid-mediated immune responses Sufficiently
to cause an increase in the mortality of the invertebrate
organism. The effective pesticidal amount for a particular
invertebrate Species can be determined by a method pro
vided for in the invention.

45

The biopesticide composition can further comprise a
chemical or biological pesticide in one or a plurality of
applications as dictated by the characteristics of the particu
lar invertebrate species to be controlled or eradicated. The
chemical or biological pesticides currently in use rarely
result in total control or eradication of the invertebrate

50
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Species. Resistant or Surviving invertebrate larvae or adults
Simultaneously or Subsequently exposed to a biological
agent which inhibits eicosanoid biological activity can
exhibit an inhibition of immune responses, an increase in
Susceptibility to infectious disease, and an increase in mor
tality. The biologically active agent can act together with
other biological control agents, like Bacillus thurigiensis.
The invention also provides a method for altering the
health of invertebrate animals by administering an effective
immunoregulatory amount of a pharmaceutical composition
containing a biologically active agent which modulates
eicosanoid-mediated immune responses. An effective immu
noregulatory amount is that amount of the biologically
active agent which results in a change in the immune
response. The pharmaceutical composition is administered
by combining it with a food or water Source and feeding it
to the invertebrate Species, by injecting, or preferably by
Spraying the composition onto the invertebrate and/or its
food or water Source. The composition can be formulated

6,099,834
S
into a liquid, powder, granules, or Sustained release and/or
macro/micro capsules. The composition can further com
prise antioxidants, UV protectants, and Sustained release
polymers.
A treatment method is provided wherein the biologically
active agent is administered to an invertebrate Species in an
amount to decrease immune response capabilities making
the invertebrate more Susceptible to infectious disease and
less likely to Survive. A similar treatment method provides
for administration of the biologically active agent in an
effective amount to enhance immune response capabilities,
making the organism leSS Susceptible to infectious disease
and more likely to Survive an infectious disease challenge.
The invention also provides a method of controlling the
growth of invertebrate pests by administering an effective
pesticidal amount of a biopesticide composition to an inver
tebrate species until growth is effectively inhibited. The
biopesticide composition is composed of at least one bio
logically active agent which inhibits eicosanoid-mediated
immune responses and a physiological carrier. The compo
Sition is administered by combining it with a food or water
Source and feeding it to the invertebrate Species, injecting,
and preferably by Spraying the biopesticide composition
onto the invertebrate and/or its food and water Source. An

effective biopesticidal amount is that amount of the biologi
cally active agent which inhibits the eicosanoid-mediated
immune response Sufficiently to cause an increase in the
mortality of the invertebrate species. The composition is
administered in a Single or a plurality of applications until
the growth of the invertebrate species is effectively inhib

6
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ited.
DETAILED DESCRIPTION OF THE
INVENTION

The pharmaceutical composition useful to alter the health
of invertebrate organisms is formed by mixing an effective
immunoregulatory amount of at least one biologically active
agent which modulates eicosanoid-mediated immune
responses and a physiologically acceptable or compatible
carrier. The biologically active agent can act to inhibit or
enhance eicosanoid-mediated immune responses. The agent
is also preferably long-acting and orally active. An effective
immunoregulatory amount of the biologically active agent
which results in a change in the immune response of the
invertebrate can be determined by the method provided in
the present invention.
Agents which can inhibit eicosanoid biological activity
include antagonists of prostaglandins, leukotrienes and
arachidonic acid, altered intermediates or enzymes of
eicosanoid biosynthetic pathways, inhibitors of Signal mol
ecules which turn on eicosanoid biosynthesis, and,
preferably, inhibitors of the eicosanoid biosynthetic path
way. Agents which can enhance or Stimulate invertebrate
eicosanoid biological activity include agents which Stimu
late the enzymes of eicosanoid biosynthetic pathway, altered
enzymes of the eicosanoid biosynthetic pathway, agents
which Stimulate Signal molecules which turn on eicosanoid
biosynthesis, inhibitors of eicosanoid inactivating enzymes
like dehydrogenases and reductases, and preferably
prostaglandins, leukotrienes, arachidonic acid and analogs
thereof. Alternatively, the biologically active agent can be a
genetically engineered organism, preferably an invertebrate
pathogen, which expresses, Secretes and delivers an agent
which alters eicosanoid biological activity.
The biologically active agent is Substantially Soluble or
dispersible in a Suitable carrier which functions to assist
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delivery of the agent to the appropriate Site. The carrier is
physiologically acceptable or compatible with living organ
isms including invertebrates, plants, fish, and other verte
brates. The composition can further be comprised of a
Surface-active agent which increases adherence and/or pen
etration of the biologically active agent to the target Site.
The pharmaceutical composition is administered in an
effective immunoregulatory amount to an invertebrate
organism by feeding by injecting or preferably by Spraying
the invertebrate Species and/or its food or water Source. An
effective immunoregulatory amount is that amount of the
biologically active agent which results in a change in the
immune response. Accordingly, the composition can be used
to treat invertebrate Species to enhance or inhibit immune
response capabilities of the organism.
The invention also provides a biopesticide formulation
and method of using the biopesticide formulation to control
or eradicate invertebrate pests. The biopesticide composition
is comprised of an effective pesticidal amount of at least one
biologically active agent which inhibits eicosanoid
mediated immune responses of an invertebrate organism and
a physiological compatible carrier. An effective pesticidal
amount is that amount of the biologically active agent which
inhibits eicosanoid-mediate immune response Sufficiently to
cause an increase in the mortality of the invertebrate organ
ism. Accordingly, the invention provides for a method of
using the biopesticide composition to control the growth of
or eradicate invertebrate pests.
Biologically Active Agents Which Modulate Invertebrate
Eicosanoid-Mediated Immune Responses
Biologically active agents useful in the invention can
modulate eicosanoid-mediated immune responses in inver
tebrates. The role, if any, of eicosanoids in invertebrate
immune responses was not previously known. The present
invention has identified that eicosanoids mediate immune

responses in invertebrates, including early immune
responses, and provides for pharmaceutical and/or biopes
ticide compositions which can be used to modulate
eicosanoid-mediated immune responses and alter the health
of invertebrate Species.
Eicosanoids are a family of biologically potent lipid acids.
Examples of naturally occurring eicosanoids include pros
taglandins E, F, A, B, C, D and derivatives thereof, leukot
rienes LTA, LTB, LTC, LTD, and LTE and derivatives
thereof, and thromboxanes A and B and derivatives
thereof. The compounds are biosynthetically produced in
many Species by enzymic conversion of polyunsaturated
fatty acids. Chemical Synthesis of eicosanoid and eicosanoid
analogs are well known in the art. See, for example, the
Corey synthesis described in E. Corey et al. J. Am. Chem.

Soc., 91:535 (1970), which is hereby incorporated by
55
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reference, which provides for the Synthesis of naturally
occurring PGE, PGF, and intermediates which are exten
Sively used in the Synthesis of prostaglandin analogs.
Other chemical Syntheses of eicosanoids are reported in

R. Kelley et al., J. Am. Chem. Soc., 95:2746 (1973); D.
White, Tetrahedron Lett., 1753 (1976); R. Newton et al.,
Tetrahedron, 36:2163 (1980) (synthesis of prostaglandins);
C. Sih et al., J. Am. Chem. Soc., 97:865 (1975)
(prostaglandin Synthesis involving the 1,4 addition of an
organometallic reagent to O-3 unsaturated ketone function);
M. Hayashi et al., J. Org. Chem., 38:2115 (1973) (synthesis
of prostaglandin D); R. Bindra et al., in ProStaglandin
Synthesis, Academic Press, N.Y. at pages 291-330 ()1977)
(partial synthesis of prostaglandins A, B and C); N. Porter et
al., J. Am. Chem. Soc., 102:1183 (1980) (synthesis of
prostaglandin endoperoxides PGH and PGH); R. Newton
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et al., Synthesis at page 449 (1984) (synthesis of
prostacyclins, PGIS, and thromboxanes); B. Samuelsson,
Science, 220:568 (1983) and J. Atkinson et al., in Handbook
of Eicosanoids, ProStaglandins and Related Lipids, Vol. 1B,
A. Willie ed., CRC Press, Boca Raton, Fla., at pages
175–263 (1989) (synthesis of leukotrienes and biological
activity); and R. Bindra et al. in ProStaglandin Synthesis,
Academic Press, N.Y. at pages 337-348 (1977) (chemical
interconversion of different prostaglandin families), which
are hereby incorporated by reference.
Eicosanoid biosynthesis in vertebrate Species has been
described in Kirk-Othmer Concise Encyclopedia of Chemi
cal Technology, 3rd edition, at pages 714 to 719 (1984),
which is hereby incorporated by reference. Biosynthesis of
eicosanoids begins with the conversion of unesterified poly
unsaturated fatty acids to arachidonic acid. Unesterified
polyunsaturated acids can be obtained from the diet or
alternatively from membrane phospholipids by the action of
phospholipases. Arachidonic acid can be converted via
enzymatic activity of cyclooxygenase to unstable
endoperoxides, such as PGG and PGH, which can then be
converted to prostaglandins and thromboxane S.
Alternatively, arachidonic acid can be enzymatically con
verted by lipoxygenase enzyme activity to form leukot
rienes. Although not meant to be a limitation of the
invention, it is believed that eicosanoid biosynthesis in
invertebrates occurs via Similar enzymatic action as that of
eicosanoid biosynthesis in Vertebrate Species.
Eicosanoid biosynthesis in invertebrates is known to
occur as prostaglandins and hydroxyeicosatetraenoic acids
are present in invertebrate tissues. Precursor polyunsaturated
fatty acids, like Omega-3 polyenoic acids, arachidonic acid,
and eicosatrieneoic acids, are present in fatty acid and
phospholipid populations of invertebrate Species. Inhibitors
of prostaglandin biosynthesis, like glucocorticoids and non
Steroidal anti-inflammatory drugs, act to prevent prostaglan
din biosynthesis in invertebrate tissues. More Specifically,
inhibitors of cyclooxygenase, like acetyl Salicylic acid,
indicate the presence of cyclooxygenase activity by inhibi
tion of prostaglandin-mediated oviposition behavior in Silk
moths. Phospholipase inhibitors, like glucocorticoids, indi
cate the presence of phospholipase enzymatic activity by
inhibition of the production of arachidonic acid from mem
brane phospholipid precursors. Inhibitors of lipoxygenase,
like esculetin, indicate the presence of lipoxygenase enzy
matic activity by inhibiting the eicosanoid-mediated host
penetration behavior of the blood fluke Schistosoma man

8
Sponges, echinoderms, arthropods, mollusks, and rotifers.
Eicosanoids can mediate egg-laying behavior in crickets,
hatching of barnacles, egg production in Snails, Spawning
behavior of abalone, spawning behavior of the Pacific
oyster, Osmoregulation and water transport in Modiolus
demissuSS, host skin penetration of blood flukes, and evasion
of host defense mechanisms by SchistoSoma manSOni. A
more detailed description of these functions of eicosanoids
in invertebrate species is provided by D. Stanley-Samuelson
et al., in Progress in Comparative Endocrinology, Wiley

Liss Inc., at pages 614-619 (1990), which is hereby incor
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invention, it is believed that eicosanoids mediate immune
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meant to be a limitation on this invention, it is believed that

initiation of eicosanoid biosynthesis in invertebrates could
occur in a similar manner.

Little is known about the Spectrum of biological activity
of eicosanoids in invertebrate species. Eicosanoids have
been identified in a wide variety of invertebrates including

immune responses can provide for a decrease in Suscepti
bility to infectious disease and a decrease in mortality of the
invertebrate Species. The biologically active agent can also
be one which acts primarily to modulate eicosanoid
mediated immune response without modifying or altering
other biological functions of the invertebrate. The biologi
cally active agent is preferably one which has long duration
and is orally active.
An effective amount of the biologically active agent
depends in part on the type of invertebrate Species, the size
of the invertebrate, the method of administration, and the

phosphate (cAMP), activation of phospholipases with cleav

age of arachidonic acid from phospholipids, and conversion
of arachidonic acid to prostaglandins and thromboxanes via
cyclooxygenase catalyzed oxidation, and to leukotrienes via
enzymatic action of a lipoxygenase in the cell. The newly
Synthesized proStaglandins, thromboxanes and leukotrienes
can be Secreted by the cell and act to mediate Stimulation of
chemotaxis, chemokinesis, phagocytosis, and adherence
responses of neutrophils and macrophages. Although not

responses in invertebrates and provide for pharmaceutical
and/or biopesticide compositions which can modulate
eicosanoid-mediated immune responses.
The biologically active agents of the invention are those
which modulate immunoregulatory eicosanoid biological
activity in invertebrates. The biologically active agent which
modulates immunoregulatory eicosanoid biological activity
in invertebrates can be selected from the group of com
pounds known to modulate vertebrate eicosanoid biological
activity and tested in invertebrates to determine whether and
what amount of the biologically active agent modulates
invertebrate immune responses. Alternatively, the biologi
cally active compound can be a novel compound which
modulates eicosanoid-mediated immune response in inver
tebrates. A modulation in the invertebrate immune response
is determined in the method provided in the invention by
detecting an increase or decrease in the growth of an
infectious agent in the invertebrate Species in comparison to
untreated control population of the invertebrate Species.
Agents which inhibit invertebrate eicosanoid-mediated
immune responses can provide for an increase in Suscepti
bility to disease and an increase in mortality. Agents which
enhance or Stimulate invertebrate eicosanoid-mediated

SOni.

In vertebrate Species, eicosanoid biosynthesis is initiated
by a membrane-mediated event, like phagocytosis or bind
ing of an antigen to receptors, which can trigger an influx of
calcium ions, a transient increase in cyclic adenosine mono

porated by reference.
It was not previously known whether eicosanoids mediate
immune responses in invertebrates. Invertebrate immune
response Systems are not well characterized and may func
tion significantly differently from that of the vertebrate
Species. Although not meant to be a limitation of the
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type of biologically active agent. Routes of administration
can include absorption of the agent through skin and exterior
Surfaces of the invertebrate species, ingestion of the agent
through the mouth or gills including from a food or water
Source, and injecting the biologically active agent. The route
of administration chosen will depend on the type of inver
tebrate Species and the Stage of the life cycle when the
biologically active agent is administered. For example, when
the compositions of the invention are administered to the
larval Stage, the route of administration is preferably by
ingestion of the compositions of the invention in combina
tion with food or water Source. The compositions can also be
administered to larvae by absorption through skin and
exterior Surfaces as many larvae Soft external Surfaces than
the adult Stage exoskeletons, cuticles, or shells. If the
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Inhibitors can include antagonists of prostaglandins,
leukotrienes, and arachidonic acid, inhibitors of the enzymes
of the eicosanoid biosynthetic pathway, altered intermedi
ates or enzymes of eicosanoid biosynthetic pathways, inhibi
tors of release of prostaglandins, leukotrienes and throm
boxanes from cells, and inhibitors of Signal molecules which
turn on eicosanoid biosynthesis. Preferably, the biologically
active agent is an inhibitor of the enzymes of the biosyn
thetic pathway, and more preferably, the inhibitor is a
peptide which blocks the active Side of an enzyme in the
eicosanoid biosynthetic pathway.
Examples of inhibitors of eicosanoid biosynthesis include

invertebrate is an adult crustacean, the compositions are
preferably administered via ingestion including ingestion
with a food Source. The composition is preferably admin
istered to agricultural pests by Spraying the affected plants
followed by ingestion of the plant tissues coated with the
compositions of the invention. Methods of administration
suitable for particular invertebrates are well known in the
art, Some of which are described in R. Samson in Funda

mental and Applied Aspects of Invertebrate Pathology, Pro
ceedings of Fourth International Colloquium of Invertebrate
Pathology at pages 597–687, the disclosure of which is
hereby incorporated by reference.
An effective amount for the particular invertebrate Species
is preferably that amount of the biologically active agent
which results in a change in the immune response. The
change in the immune response for a particular invertebrate
Species can be identified by an increase or decrease in
Susceptibility of the invertebrate species to an infectious
agent and can be determined by the method provided in the

cinnamic acid and derivatives thereof, arachidonic acid

derivatives, glucocorticoids, dihydroxybenzopyran ketones
15

invention. Preferably, dosages can range from about 1x10
Aug/gm body weight to 1x10 ug/gm body weight, and more
preferably, about 1x10 ug/gm body weight to 1x10
tag/gm body weight, and most preferably, about 1x10"

tug/gm body weight to 1 lug/gm body weight
Examples of agents which modulate eicosanoid-mediated
immune response are those which alter formation and/or
biological activity of the eicosanoids. These agents include
agents that affect Signal molecules which turn on eicosanoid
biosynthesis, agents which modify the eicosanoid biosyn
thesis and/or formation, and agents which modify
eicosanoid biological action. Agents that affect Signal mol
ecules can include agents which modulate the levels of
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cyclooxygenase include Eb Selen (2-phenyl-1,2benzisoselenazol-3(2H)-one), curcumin, ETYA (5,8,11,14
eicosatetraynoic acid), naproxen, indomethacin, nonsteroi

dal anti-inflammatory drugs Such as Salicylic acid acetates
and derivatives thereof, phenidone, benoxaprofen, and REV
5741. Inhibitors of phospholipase include phosphorylcho

cAMP or Ca' ions, or those which modulate the activity of

the phospholipases and protein kinases. Agents which alter
or modify eicosanoid formation or biosynthesis can include
altered enzymes of eicosanoid biosynthetic pathways,
altered intermediates of eicosanoid biosynthetic pathways,
Specific active site inhibitors of eicosanoid biosynthetic
enzymes, and other competitive and non-competitive inhibi
tors of eicosanoid biosynthesis. Agents which modify
eicosanoid biological action can include eicosanoid analogs,
eicosanoid antagonists, eicosanoid agonists, inhibitors of
inactivating enzymes like inhibitors of eicosanoid dehydro
genases and reductases, and agents which interfere with the
release of eicosanoids from cells. The eicosanoid analogs
can be modified to enhance selectivity for invertebrate
immune responses. Eicosanoid analogs can also preferably
be modified to have longer duration, to act orally, and to
have increased potency over naturally occurring
eicosanoids.

The biologically active agent can also be a genetically
engineered organism which expresses, Secretes and delivers
a biologically active agent which alters or modulates
eicosanoid-mediated immune response in invertebrates.
Biologically Active Agents Which Inhibit Eicosanoid
Mediated Immune Responses
Biologically active agents useful in the pharmaceutical
and/or biopesticide compositions inhibit eicosanoid biologi
cal activity and provide for an inhibition of immune
responses and an increase in Susceptibility to disease. The
inhibitors can also provide for an increase in mortality which
can result from inability to clear an infection with opportu
nistic and other invertebrate pathogens, an inability to com
pletely repair wounds, and an increase in Susceptibility to
cancer. The inhibitors can be modified to selectively modu
late the immune responses. The inhibitors are preferably
long-acting and orally active.

and derivatives thereof, methanoleukotrienes and deriva

tives thereof, binapthalene derivatives, naphthalene acetic
acid derivatives, phosphorylcholine derivatives, indole ace
tic acid derivatives, dihydropyridine carboxylic acid
derivatives, phenanthrene carboxylic acids and derivatives
thereof, Salicylic acid acetate and derivatives thereof,
neomycins, benzoxazoleacetic acids and derivatives thereof,
and dihydroxyanthrone derivatives and mixtures thereof.
Specific examples of inhibitors of eicosanoid biosynthesis
include inhibitors of the eicosanoid biosynthetic enzymes:
phospholipase A2, cyclooxygenase, 5-lipoxygenase,
12-lipoxygenase, and 15-lipoxygenase. Inhibitors of

line and derivatives thereof, glucocorticoids, DEDA (7,7dimethyl-eicosadienoic acid), neomycins and derivatives
35

thereof, aminocephalosporanic acid and derivatives thereof,
chlorpromazine HCl and derivatives thereof, dihydropyri
dine carboxylic acid and derivatives thereof, manoalide,
phenanthrene carboxylic acids and derivatives thereof, and
compound 48/80. Inhibitors of lipoxygenase enzymes

40

include 5-lipoxygenase inhibitors: Ebselen, REV-5901 (23(1-hydroxy hexyl)phenoxy methylquinoline
hydrochloride), REV-5367, REV-5747, REV-5827, REV
5875, REV-5965, REV-6080, 12-lipoxygenase inhibitors:
REV-5747, REV-5827, and REV-5901, 15-lipoxygenase

45

inhibitors: REV-5367 and phenidone (1-phenyl-3pyrazolidinone); and other lipoxygenase enzyme inhibitors
including: anthralin, Baicalein (5,6,7-trihydroxyflavone),
caffeic acid, curcumin, cinnamic acid and derivatives

thereof, arachidonic acid derivatives, DEDA, dipyridamole,
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ETI (5,8,11-eicosatriynoic acid), esculetin, gossypol,
indomethacin, NDGA (nordihydroguaiaretic acid),

phenidone, benoxaprofen, methanoleukotrienes and deriva

tives thereof, AA-861 (2-(12-hydroxy-5,10-dodecadiynyl)3,5,6-trimethyl-p-benzoquinone), nafazatrom, and querce
55
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tin.

Inhibitors can include antagonists and/or agonists of
prostaglandins, leukotrienes and arachidonic acid. These
inhibitors can prevent the biological action of eicosanoids by
binding to receptorS and active Sites of enzymes and/or
preventing release of eicosanoids from cells. Specific
examples of these agents include the eicosanoid antagonists

13-APA (13-aZaprostanoic acid), carbacyclin, CTA
(carbocyclic thromboxane A2 (CAS Registry No. 74034
56-3)), U-44069 (9,11-dide oxy-11 - C.-9- C.epoxymethanoprostaglandin F2C), U-46619 (cromolyn),
DSCG ((15S)-15-hydroxy-11-C-9-C-(epoxymethano)
prosta-5(Z), 13(E)dienoic acid), Oxatomide, PTA (pinane
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thromboxane A2), Xanthines and derivatives thereof, and

12
Specific examples of Simulators of eicosanoid biosynthe
sis include omega group fatty acids, phospholipases and
derivatives thereof, calcium ionophors, eicosanoid biosyn
thetic enzymes and derivatives thereof, eicosanoid biosyn

mixtures thereof.

Inhibitors can include inhibitors of Signal transduction
molecules. Signal transduction molecules include calcium
ions, phospholipases, cyclic AMP, and protein kinases. Spe
cific examples of Such inhibitors include A-3, erbstatin,
genistein, H-7, K-252a, phloretin, Sphingosine, StauroSporin,
calcium channel blockers, glucocorticoids, and mixtures

thetic intermediates, arachidonic acids and derivatives

15

thereof, and mixtures thereof. Omega group fatty acids and
arachidonic acid and derivatives thereof provide precursors
for eicosanoid biosynthesis. Eicosanoid biosynthetic
enzymes include phospholipases, cyclooxygenases, and
lipoxygenases. Agents which provide Signal molecules
include phospholipases and calcium ionophors.
Altered biosynthetic enzymes are derivatives of phospho
lip a Se A2, cyclooxygenase, 5-lip OXygenase,
12-lipoxygenase, and 15-lipoxygenase enzymes. The altered
enzymes are enzymatically active and can function in
eicosanoid biosynthetic pathways. Alterations can be made
to the amino acid Sequences of the enzyme and preferably
alterations are made to the amino acid Sequence of the active
Site of the eicosanoid biosynthetic enzymes.
Preferably the biologically active agent is an analog of
prostaglandins, leukotrienes or arachidonic acid, and more
preferably an analog which is orally active, has prolonged
duration of biological activity, and increased potency in
invertebrates. Analogs are formed by Synthetic modification
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of the chemical Structure of eicosanoids. Modifications to

thereof.

Altered intermediates of eicosanoid biosynthesis are ana
logs of prostaglandins, leukotrienes and thromboxanes
which compete with naturally occurring eicosanoid inter
mediates and inhibit the biosynthetic enzyme activity,
thereby inhibiting production of eicosanoids. Altered inter
mediates are not active and can be formed by a modification
of the Structure of eicosanoids, including modification of
carbon-15, the carboxylic acid Sidechain and the aliphatic
Sidechain of prostaglandins, B-Cs. Sidechain of prostaglan
dins and thromboxanes, and the 2,6-diaxobicycloheptane
skeleton of thromboxanes.

Altered enzymes of the eicosanoid biosynthetic pathway
include derivatives of phospholipase A, cyclooxygenase,
5-lipoxygenase, 12-lipoxygenase, and 15-lipoxygenase. The
altered enzymes which Serve as inhibitors of eicosanoid
mediated immune response are inactive enzymatically and
bind to the intermediates in eicosanoid biosynthesis. The
altered enzymes compete with the naturally occurring
enzymes by binding intermediates in the biosynthesis, but
Since the altered enzymes are enzymatically inactive,
eicosanoid biosynthesis cannot proceed, thereby inhibiting
production of eicosanoids. Altered enzymes which are inac
tive can be formed by modification of the amino acid
Sequence of the enzyme and preferably, the amino acid
Sequence of the active Site of the particular eicosanoid
biosynthetic enzyme is altered.
The biologically active agent which inhibits eicosanoid
mediated immune responses is Substantially Soluble or dis
persible in the carrier. The inhibitor is combined with the
carrier in an effective amount to form a pharmaceutical
composition. The types of and effective amounts of the
inhibitor are those agents and amounts which inhibit
immune responses in the invertebrate Species as determined
by an increase in the growth of an infectious agent in the
invertebrate Species in comparison to the untreated control
population.
Biologically Active Agents Which Enhance Eicosanoid Bio
logical Activity
Biologically active agents which Stimulate or enhance
eicosanoid-mediated immune responses can provide for a
decrease in the Susceptibility to disease, including infectious
disease. The Stimulating agents can also provide for a
decrease in the mortality. The Stimulating agents can be
modified to more Selectively modulate immune responses.
Preferably the Stimulating agents are long-acting and orally
active.

Agents which can enhance or Stimulate invertebrate
eicosanoid-mediated immune response include
prostaglandins, leukotrienes, arachidonic acid and analogs
thereof, agents which Stimulate the enzyme of eicosanoid
biosynthetic pathways, altered enzymes of the eicosanoid
biosynthetic pathway, and agents which Stimulate Signal
molecule which turn on eicosanoid biosynthesis. Preferably,
the biologically active agent is an analog of a prostaglandin,
leukotriene, or arachidonic acid, and more preferably an
analog which is orally active, has prolonged duration of
biological activity, and increased potency when compared
with naturally occurring eicosanoids.

carbon-15, the carboxylic acid Sidechain and the aliphatic
Sidechain of prostaglandins, the B-Cs. Sidechain of proStag
landins and thromboxanes, and the 2,6-diaxobicycloheptane
skeleton of thromboxanes can result in a longer-acting,
orally active, and more potent analogs. Modification of
eicosanoids at the Sites can also provide an analog which
acts Substantially Selectively to modulate invertebrate
immune responses. Specific examples of longer-acting and
35

orally active analogs of eicosanoids include 15(R)-15
methyl PGE, 11(R)-11-deoxy-11,16,16-trimethyl-PGE,
dl-4,5-didehydro-16-phenoxy-17, 18,19,20-tetranor-PGE

methyl ester, d1-(11R,15RS)-11, 15-dihydroxy-15-methyl-9(15RS)-15-deoxy-16-hydroxy-16-vinyl-PGE methyl ester,
OXO-13-thiaprostanoic acid p-benzamidophenylester, dil
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and mixtures thereof.

The biologically active agent which Stimulates
eicosanoid-mediated immune responses is Substantially
Soluble or dispersible in the carrier. The Stimulating agent is
combined with the carrier in an effective amount to form a
45
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pharmaceutical composition. The types and effective
amounts of Stimulating agents are those agents and amounts
which enhance immune responses in the invertebrate Species
as determined by a decrease in the growth of an infectious
agent in comparison to untreated control population.
The pharmaceutical composition is administered to inver
tebrate Species to enhance immune responses and decrease
Susceptibility of the invertebrate to disease, including infec
tious disease. The Stimulating agent can also provide a
decrease in mortality by increasing resistance to infectious
disease, enhancing wound repair, and increasing resistance
to cancer. Accordingly, the pharmaceutical composition can
be used in prophylaxis and treatment of disease, including
infectious disease, in commercially important invertebrate
Species.
Biologically Active Agents Which Are Genetically Engi
neered Organisms
The biologically active agent can also be a genetically
engineered organism which expresses, Secretes and delivers
an agent which alters or modulates eicosanoid-mediated
immune responses to invertebrates. The agent which alters
eicosanoid-mediated immune responses can be one that
enhances or inhibits immune responses in invertebrates. For
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example, the agent may be a peptide which inhibits an active
Site of eicosanoid biosynthetic enzyme or an altered
eicosanoid inactivating enzyme.
Suitable organisms include genetically engineered yeast,
bacteria, Viruses, plants or fungi. Preferably the organism is
a microorganism which can infect and grow in the particular
invertebrate Species and, more preferably, a pathogenic
microorganism. Genetically engineered pathogens of the
invention can invade and produce disease in invertebrate
Species as well as deliver inhibitors of eicosanoid-mediated
immune responses.
Genes can be cloned and introduced into the organisms by
standard recombinant DNA methods. Such techniques are
well known to those of skill in the art and are outlined in

Guide to Molecular Cloning Techniques. Methods in
Enzymology, Vol. 152, S. Berger and A. Kimal, ed., Aca

15

demic Press, Inc., San Diego, Calif. (1987), which is hereby

incorporated by reference. Genes can be introduced into
cells by vector-mediated transformation with vectors like
Viruses and plasmids, or by physical methods of transfor
mation including use of microprojectiles, microinjection,
biolistic transformation, electroporation, incubation with
calcium-precipitated DNA, and incubation with liposomes
containing foreign DNA. See M. Fromm et al., PNAS,

82:5824 (1984) (electroporation); T. M. Klein et al., Nature,
327:70 (1987) (microprojectiles); P. Lurquin et al., Plant
Science Lett., 25:133 (1982) (liposomes), the disclosures of
which are hereby incorporated by reference.
Genes which can be introduced into organisms as a Single
gene or a cassette containing multiple genes. For example,
an expression cassette can include genes for Selective mark
erS like antibiotic resistance as well as genes encoding one
or more biologically active agents which inhibit or enhance
eicosanoid-mediated immune responses. Genes encoding
the biologically active agents can be modified to provide for
enhanced expression and/or Secretion of the biologically
active agent from the microorganism. Genes can also be
hybrid genes with one DNA sequence encoding a transit
peptide which allows for targeting and transport of the
remainder of the molecule to the invertebrate target cell, and
a Second DNA sequence encoding at least one biologically
active agent to be delivered to the invertebrate target cell.
Specific examples of genes which can be used to trans
form organisms, either alone or as a part of an expression
cassette, include genes encoding eicosanoid biosynthetic
enzymes and mutants thereof, genes encoding eicosanoid
inactivating reductase and dehydrogenase enzymes and
mutants thereof, genes encoding altered Signal transduction
molecules and mutants thereof, and genes encoding peptide
inhibitors of the active sites of eicosanoid biosynthetic
enzymes and mutants thereof.
In a preferred version, an invertebrate pathogenic agent,
as for example, Serratia marceScens, is transformed with the
gene encoding a peptide which blockS or inhibits the active
Site of an eicosanoid biosynthetic pathway enzyme. The
pathogenic agent is transformed with a plasmid vector also
containing a Selectable marker or reporter gene. The trans
formed pathogen is Selected using the Selectable marker or
reporter gene and expresses, Secretes and deliverS Sufficient
amount of the peptide inhibitor to the invertebrate Species to
provide an inhibition of the immune response.
The genetically transformed organism is Substantially
Soluble or dispersible in the carrier. The genetically engi
neered organism is combined with the carrier in an effective
amount to form a pharmaceutical and/or biopesticide com
position. An effective amount of genetically engineered
organism is that amount which alters or modulates the
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invertebrate Species immune responses. A genetically engi
neered non-pathogenic organism which infects and grows,
can deliver immunostimulating agents to commercially
valuable invertebrate Species. The preferred version pro
vides for a genetically engineered pathogen which can Serve
as a biopesticide for a particular invertebrate pest.
Method for Determining Whether and What Amount of the
Biologically Active Agent Is Effective to Modulate Immune
Responses in Invertebrates
The invention provides a method for determining whether
and what amounts of the biologically active agent result in
a change in immune responses of the particular invertebrate
Species. The method involves administering different dos
ages of the biologically active agent in the carrier to the
particular invertebrate Species followed by inoculation of the
invertebrate with an effective amount of an infectious agent,
preferably a pathogen. A control group of organisms
receives the carrier alone followed by inoculation with the
infectious agent. After an effective incubation period to
provide for Sufficient growth of the infectious agent, pref
erably about 0.5 hours to 10 hours post-infection and more
preferably about 1–5 hours post-infection, tissue or
hemolymph samples are withdrawn from the invertebrate
organism, extracted in physiological Solution, and incubated
with growth medium. Suitable physiological Solutions
include physiological Salt Solutions of Sodium chloride,
Sodium phosphate, and Sodium citrate. The growth medium
is incubated until Sufficient growth of the infectious agent
occurs, and the amount of infectious agent present in the
Sample is determined. A change in the immune response is
determined by comparing the amount of infectious agent
recovered from the tissue samples from the invertebrate
organisms receiving different doses of the biologically
active agent with the amount of infectious agents recovered
from control organisms. An increase or decrease in the
amount of infectious agent recovered from organisms
treated with the biologically active agent, and preferably, an
increase or decrease at least about 2-fold, indicates a change
in the immune response. An effective immunoregulatory
amount can be calculated by determining which dosages of
the biologically active agent result in a change in the
immune response.
In a preferred version, an invertebrate agricultural pest
Species, as for example Manduca Sexta, is injected with
different dosages of dexamethasone, an inhibitor of
eicosanoid biosynthesis. The organism is then injected with
a pathogenic agent for the particular invertebrate Species,
like, for example, Serratia marceScens. The control group
receives absolute ethanol followed by inoculation with the
pathogenic agent. After about 1 hour post-infection,
hemolymph Samples are withdrawn, extracted, diluted, and
plated on Standard method agar plates to provide for growth
of the pathogenic agent. Serratia marceScens colonies are
incubated for 40–48 hours to provide for sufficient bacterial
growth. AS the dosage of the inhibitor is increased, the
amount of pathogenic agent recovered from the tissue is
determined. The lower doses of the inhibitor resulting in
about 2-fold increase in the amount of the recovered bacteria

and higher doses result in at least about a 20-fold increase
60

over the amount of bacteria recovered from the control. An
increase of at least about 2-fold in the amount of the

pathogenic agent recovered from tissue samples of inverte
brates treated with the inhibitor indicates an inhibition in the
65

immune response.
Infectious agents useful in the method are those which can
infect and grow in a particular invertebrate Species, and are
preferably pathogenic microorganisms. Suitable infectious
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agents and effective amounts for a particular invertebrate
Species to be tested in the method are known to those of Skill
in the art and are outlined in A. Sparks in Synopsis of

Surface agents, cationic Surface agents, nonionic Surface
agents, and ampholytic Surface active agents.
Surface active agents are present in the carrier in amounts
effective to decrease Surface tension, increase wettability,
increase adherence to the target Site, and increase penetra
tion of the biologically active agent. Specific examples of
the Surface active agents are provided in Adjuvants for
Herbicides, published by Weed Science Society of America,

Invertebrate Pathology, Elsevier, at pages 133-382 (1985)

and in R. Samson et al. in Fundamental and Applied Aspects
of Invertebrate Pathogens, Proceedings of the Fourth Inter
national Colloquium of Invertebrate Pathology, at pages

1-362 (1986), the disclosures of which are hereby incorpo

rated by reference. Appropriate growth medium and growth
conditions to recover the infectious agent from the tissue
samples of the invertebrate are known to those of skill in the

R. Hodgson, ed., at Chapter 8, pp. 119-137 (1982), the
disclosure of which is hereby incorporated by reference.

The carrier can also include additives that enhance Sta

art.

The dosage range of the biologically active agent admin
istered in the method depends on the size of the invertebrate,
the type of biologically active agent, and the method of
administration. Preferably, different dosages ranging from

15

about 1x10 ug/gm body weight to 1x10 ug/gm body
weight, and more preferably, about 1x10 ug/gm body
weight to 1x10 ug/gm body weight, and most preferably,
about 1x10" ug/gm body weight to 1 lug/gm body weight

mixtures thereof.

can be administered to the invertebrate Species to determine
whether and what amounts of the particular biologically
active agent modulate eicosanoid-mediate immune
responses in the particular invertebrate Species.
Carriers

The biologically active agent is combined with a Suitable
carrier which functions to assist delivery of the agent to the
appropriate Site. The choice of carrier depends on the habitat
of the invertebrate, type of food consumed by the
invertebrate, and the physical characteristics of the biologi
cally active agent. The biologically active agent is Substan
tially Soluble or dispersible in the carrier, and the carrier is
Substantially physiologically acceptable or compatible with
invertebrates, plants, fish, and other vertebrate organisms.
The carrier can function to help the biologically active agent
adhere to plant leaves and other food Sources consumed by
the targeted invertebrate species. The carrier can also func
tion to allow the biologically active agent to adhere and/or
penetrate the external skeletons, tests, shells, or cuticles of
invertebrate species. The carrier can also be a food Source
for the invertebrate Species like plant leaves or brine Shrimp.
The carrier can be formulated into a liquid or powder or
granular mixture for Spray delivery or micro encapsulated in
liposomes and the like. For example, a pharmaceutical
composition Suitable for aerial Spraying can include an
effective amount of biologically agent mixed with dried
quart Sand and vegetable oil. Specific examples of Suitable
carriers include paraffin wax, lecithins, vegetable oil, Saline
Solutions, Salt Solutions, absolute ethanol, corn grits, Sand,
phospholipids, Sustained release polymers and mixtures
thereof. In a preferred version, the biologically active agent
is dissolved in absolute ethanol and mixed with soybean
lecithin and paraffin wax.
Sustained release polymers are those polymers that can
incorporate the biologically active agent of the invention and
provide for controlled release or delivery of the biologically
active agent. Sustained release polymers can be formulated
to provide for micro or macro encapsulation of the biologi
cally active agent. Examples of Suitable Sustained release
polymers are hydrogels, acrylates, polylactides, polyacrylic
acids, polyethylene glycols, polyglycolides, and polymers
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with leachable occluded Substances and mixtures thereof.

The carrier of the composition can be further comprised
of a Surface active agent. The Surface active agent readily
disperses in the carrier and increases the adherence and/or
penetration of the carrier and biologically active agent to a
target Site. Suitable Surface active agents include anionic

bility of and absorption of the biologically active agents.
Additives, Such as antioxidants and UV protectants, increase
Stability of the biologically active agents exposure to Sun
and oxygen. Additives which can assist in absorption of the
biologically active agents can include propylene glycol,
glycerol, urea, Sodium lauryl Sulfate, Sorbitan ethoxylates,
oleic acid, n-methyl pyrrolidone, dimethyl Sulfoxide and

65

Biopesticide Composition
Biologically active agents which inhibit eicosanoid
mediated immune responses of the present invention are
capable of functioning as biological pesticides either alone
or in combination with other pesticides. A pest management
Strategy can involve combining chemical pesticides, bio
logical pesticides, and the biopesticide inhibitors of the
present invention to provide for control eradication of target
invertebrate Species.
Agents which can inhibit invertebrate eicosanoid
mediated immune responses can include antagonists of
prostaglandins, leukotriene, and arachidonic acid, inhibitors
of the eicosanoid biosynthetic pathway, altered intermedi
ates and/or altered enzymes of the eicosanoid biosynthetic
pathways, and inhibitors of Signal molecules which turn on
eicosanoid biosynthesis. The inhibitor can be long-acting
and orally active. Preferably, the biologically active agent is
an inhibitor of the enzymes of the eicosanoid biosynthetic
pathway, and more preferably, the inhibitor is a peptide
which blocks the active site of an enzyme in the eicosanoid
biosynthetic pathway.
The biologically active agent can also be a genetically
engineered organism which expresses, Secretes and delivers
an agent which inhibits eicosanoid-mediated immune
responses of the invertebrate Species. Suitable organisms
can be genetically engineered yeast, bacteria, Viruses, plants,
or fungi. The organism is preferably a microorganism which
can infect and grow in the particular invertebrate Species and
more preferably a microorganism or pathogenic microor
ganism. Genes are cloned and introduced into the organism
by standard recombinant DNA methods and include genes
encoding the enzyme of the eicosanoid biosynthetic pathway
and mutants thereof, genes encoding altered Signal trans
duction molecules and mutants thereof, and genes encoding
peptides which block the active sites of the enzymes of the
eicosanoid biosynthetic pathway. In a preferred version, a
pathogenic bacteria, like Serratia marceScens, is trans
formed with a plasmid containing a gene encoding a peptide
which blocks or inhibits the active site of an enzyme of the
eicosanoid biosynthetic pathway, like phospholipase A.
An effective pesticidal amount of the biologically active
agent depends in part on the invertebrate Species, the size of
the invertebrate, the method of administration, and the type
of biologically active agent. An effective biopesticidal
amount is that amount of the inhibitor which sufficiently
inhibits eicosanoid-mediated immune response in the inver
tebrate to provide an increase in mortality of the invertebrate
Species and can be determined by the method of the inven
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tion. Suitable dosage ranges can include about 1x10
Aug/gm body weight to 1x10 ug/gm body weight, and more
preferably, about 1x10 ug/gm body weight to 1x10
Aug/gm body weight, and most preferably, about 1x10'

limited host range. Although not meant to be a limitation of
the Scope of the invention, it is believed that combining
known biological pesticides with the biopesticide inhibitors
of the present invention may help to increase virulence and
host range by allowing pathogens and parasites to grow
more rapidly in invertebrate Species while immune
responses of the invertebrate species are inhibited. Examples
of known biological control agents include Species of Bacil
lus thuringiensis, Bacillus popilliae, Bacillus Sphaericus,
species of Nosema, Serratia entomophila, Verticillium
lecanii, Hirsutilla thompsonii, Metarhizum anisopliae, and

tug/gm body weight to 1 lug/gm body weight. The invention
also provides a method for determining which biologically
active agents and what amounts are effective to control the
growth of the particular invertebrate species.
The biologically active agent is combined with a Suitable
carrier which functions to assist delivery of the agent to the
appropriate Site. The choice of carrier depends on the habitat
of the invertebrate, type of food consumed by the
invertebrate, and the physical characteristics of the biologi
cally active agent. The biologically active agent is Substan
tially Soluble or dispersible in the carrier, and the carrier is
Substantially physiologically acceptable or compatible with
invertebrates, plants, fish, and other vertebrate organisms.
The carrier can function to help the biologically active agent
adhere to plant leaves and other food Sources consumed by
the targeted invertebrate species. The carrier can also func
tion to allow the biologically active agent to adhere and/or
penetrate the external skeletons, tests, shells, or cuticles of
invertebrate species. The carrier can also be a food Source
for the invertebrate Species like plant leaves or brine Shrimp.
The carrier can be formulated into a liquid or powder or
granular mixture for Spray delivery or micro or macro
capsules. Suitable carriers include paraffin wax, lecithins,
vegetable oil, Saline Solutions, physiological Salt Solutions,
absolute ethanol, corn grits, Sand, membrane phospholipids,
Sustained release polymers, and mixtures thereof.
The biopesticide composition can further be comprised of
additional agents which provide for Stability and protection
of biologically active agents from environmental conditions,
like Sun and oxygen. Suitable agents include UV protectants
and antioxidants. The biopesticide composition can also be
comprised of a Surface active agent which aids in adherence
and/or penetration of the biologically active agent. Suitable
Surface active agents include anionic Surface agents, cationic
Surface agents, nonionic Surface agents, and ampholytic
Surface agents.
Known chemical pesticides are useful in combination
with the biopesticide compositions of the present invention
to control or eradicate invertebrate Species. Chemical pes
ticides are non-naturally occurring chemicals which can
non-specifically kill invertebrate Species at all Stages of their
life cycle. Chemical pesticides can persist in the environ
ment and their effects are long-lasting. However, chemical
pesticides are often not 100% effective and resistant species
of invertebrates can arise. While not limiting the scope of the
invention, it is believed that combining a chemical pesticide
with the biological pesticide inhibitors of the present inven
tion can improve efficacy of the chemical pesticide and
eliminate resistant species, allowing for the use of lower
doses of chemical pesticides. Specific examples of pesti
cides currently used in invertebrate pest control are DDT,
malathion, fenitrothion, pirimiphoSmethyl, carbamates,
propoXur, bendiocarb, chlorphoXim, prye throids,
permethrin, deltamethrin, and temephoS.
Known biological pesticides are useful in combination
with the biopesticide compositions of the present invention.
Biological pesticides consist of naturally occurring organ
isms which are host specific and are biodegradable and,
thereby, minimize the environmental contamination. Bio
logical pesticides currently in use include invertebrate
pathogens, parasites, and predators like larvivorus fish.
Biological pesticides are also not 100% effective against
invertebrate Species, in part because of low virulence and

Blauvaria bassiana.
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Inhibitors of eicosanoid-mediated immune responses use
ful as biopesticides can be combined with one or more
chemical or biological pesticides in a carrier to form a
biological pesticide composition. The biopesticide inhibitors
are compatible with the biological or chemical pesticide and
are substantially soluble or dispersible in the mixture of
carrier and chemical or biological pesticide. The biopesti
cide inhibitors are present in the composition in an amount
effective to inhibit the immune responses and provide an
increase in the mortality of the target invertebrate Species.
The composition can be administered by Spraying, injecting,
painting, brushing, or Squirting in a Single or plurality of
applications until the targeted invertebrate pest is controlled
or eradicated.

In a preferred version, an effective biopesticidal amount
of the inhibitor of eicosanoid biosynthesis, like
dexamethasone, can be combined with a known biological
pesticide, like Bacillus thuringiensis serotype H-14, by
mixing with a carrier of paraffin wax and Soybean lecithin.
This composition can be administered by Spraying to inver
tebrate pests, like mosquito larvae, of Culex pipiens, Aedes
vexans, Aedes cantans, and Anopheles maculipennis until
Sufficient control or eradication of the invertebrate species is
35
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observed.

Method for Determining Whether and What Amounts of the
Inhibitors of Eicosanoid-Mediated Immune Responses Are
Useful in the Biopesticide Compositions
The invention provides a method for determining whether
and what amounts of the biologically active inhibitors result
in an inhibition of the immune response Sufficient to increase
the mortality of the invertebrate Species in response to a
pathogenic infection. The method involves administering an
amount of the biologically active inhibitor of eicosanoid
mediated immune responses in the carrier to the particular
invertebrate species followed by inoculation of the inverte
brate with an effective amount of an infectious agent,
preferably a pathogen, to form a test population. A control
population of organisms receives the carrier alone followed
by inoculation with the infectious agent. The control and test
populations are incubated for an effective period of time to
provide for Sufficient growth of the infectious agent, pref
erably about 5 to 72 hours post-infection, and more prefer
ably about 5 to 24 hours post-infection. After the incubation,
the percentage of organisms Surviving in the test population
is compared to the percentage of organisms Surviving in the
control group. A decrease in the percentage of organisms
surviving of at least about 2-fold when compared with the
control population over the same period of time indicates
whether and what amount of the inhibitor inhibits inverte

brate immune responses Sufficiently to provide an increase
in mortality. The effective biopesticidal amount of the
inhibitor is calculated by determining which dosages of
biologically active inhibitors result in an increase in mor
tality.
In a preferred version, an invertebrate agricultural pest, as
for example Manduca Sexta, is injected with different dos
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ages of an inhibitor of eicosanoid biosynthesis, like dexam
ethasone. The invertebrate organism is injected with a
pathogenic agent for the particular invertebrate Species, like,
for example, Serratia marceScens. The control group
receives absolute ethanol followed by inoculation with a
pathogenic agent. After about 14 hours post-infection, the
number of Surviving invertebrate organisms is counted. AS
the dosage of the inhibitor is increased, the percentage of
Surviving organisms decreases. The lower doses of the
inhibitor result in about a 2-fold decrease in the percentage
of organisms Surviving and higher doses result in a 4-fold
decrease in the percentage of organisms Surviving the patho
genic infection. A decrease of at least about 2-fold in the
percentage of organisms Surviving the pathogenic infection
indicates an inhibition of the immune response Sufficient to
increase mortality of the invertebrate Species.
Infectious agents useful in the method are those which can
infect and grow in a particular invertebrate Species, and are
preferably pathogenic microorganisms. Suitable infectious
agents and effective amounts for a particular invertebrate
Species to be tested in the method are known to those of Skill
in the art and are outlined in A. Sparks in Synopsis of

invention are administered to the larval Stage, the route of
administration is preferably by ingestion of the compositions
of the invention in combination with food or water Source.

The compositions can also be administered to larvae by
5 absorption through skin and exterior Surfaces as many larvae
lack external exoskeletons, shells or cuticles. If the inver

tebrate is an adult crustacean, the compositions are prefer
ably administered via ingestion including ingestion with a
food Source. The composition is preferably administered to
10 agricultural pests by Spraying affected plants followed by
ingestion of the plant tissues coated with the compositions of
the invention by the invertebrate pest. Methods of admin
istration Suitable for particular invertebrates are well known
in the art, Some of which are described in R. Samson in

15 Fundamental and Applied Aspects of Invertebrate
Pathology, Proceedings of Fourth International Colloquium
of Invertebrate Pathology at pages 597–687, the disclosure
of which is hereby incorporated by reference.
An effective amount for the particular invertebrate Species
20 is preferably that amount of the biologically active agent
which results in a change in the immune response. A change
in the immune response can be identified by an increase or
Invertebrate Pathology, Elsevier, at pages 133-382 (1985) decrease in the Susceptibility of an invertebrate Species to an
and in R. Samson et al. in Fundamental and Applied Aspects infectious agent and can be determined by the method of the
of Invertebrate Pathogens, Proceedings of the Fourth Inter- 25 invention. Suitable dosage ranges include about 1x10
national Colloquium of Invertebrate Pathology, at pages Aug/gm body weight to 1x10 ug/gm body weight, and more

1-362 (1986), the disclosures of which are hereby incorpo

preferably, about 1x10 ug/gm body weight to 1x10

tag/gm body weight, and more preferably, about 1x10"
rated by reference.
The dosage range of the biologically active agent admin tug/gm body weight to 1 lug/gm body weight.
istered in the method depends on the size of the invertebrate, 30 The composition is administered by combining it with a
the type of biologically active agent, and the method of food or water Source and feeding it to the invertebrate
administration. Preferably, different dosages ranging from Species, by injection, or preferably by Spraying the compo

about 1x10 ug/gm body weight to 1x10 ug/gm body Sition onto the invertebrate and/or its food or Water Source.
weight, and more preferably, about 1x10 ug/gm body The composition can be administered as a liquid, powder,
weight to 1x10 ug/gm body weight, and most preferably, 35 granules, or encapsulated like, for example, in lipoSomes.
about 1x10" ug/gm body weight to 1 lug/gm body weight The composition may be sprayed onto plant leaves and
can be administered to the invertebrate Species to determine
whether and what amounts of the biologically active agent
modulate eicosanoid-mediated immune responses Suffi
ciently to provide an increase in mortality and thus are useful
in a biopesticide composition for a particular invertebrate
Species.
Method for Altering the Health of Invertebrate Animals With
the Compositions Containing Biologically Active Agents
Which Modulate Eicosanoid-Mediated Immune Responses
The present invention also provides for a method for
altering the health of invertebrate animals involving admin
istering an effective immunoregulatory amount of a compo
Sition containing a biologically active agent which modu
lates eicosanoid-mediated immune responses. The
biologically active agent can inhibit or enhance immune
responses of invertebrates. The choice of the biologically
active agent will depend on the goal of the treatment. If the
goal of the treatment is to inhibit the growth of the inver
tebrate Species, at least one inhibitor of eicosanoid-mediated
immune responses can be included in the composition. If the
goal is to protect invertebrate Species from injurious
conditions, at least one enhancer or Stimulator of eicosanoid

mediated immune responses can be included in the compo
Sition.

An effective amount of the biologically active agent
depends, in part, on the type of invertebrate Species, the size
of the invertebrate, the method of administration, and the

type of biologically active agent. The route of administration
chosen will depend on the type of invertebrate Species and
the Stage of the life cycle when the biologically active agent
is administered. For example, when the compositions of the

foliage or water Sources by a low-pressure backpack Sprayer,
or by aerial spraying. The composition is delivered to the
target invertebrate Species by ingestion, including ingestion
40 of a food or water Source containing the biologically active
agent, by penetration through the Outer Surface of the
invertebrate body including wound penetration, and by
injection. The composition can also be delivered by geneti
cally engineered microorganism which, as it grows in the
45 invertebrate Species, expresses, Secretes and delivers the
biologically active agent. The composition can be adminis
tered at all Stages if the life cycle of the invertebrate Species,
but is preferably administered to the larval stage. The
composition can be administered as a Single application or
50 a plurality of applications until the goal of the treatment is
achieved.

When the invertebrate Species is an important food Source
of commercial value, like mollusks or crustaceans, the

invention also provides a treatment method useful to protect
55 the Species from injurious conditions and/or treat disease of
the Species. The method involves administering a pharma
ceutical composition containing an enhancer or Stimulator of
eicosanoid-mediated immune response in an amount effec
tive to enhance immune responses. The enhanced immune
60 response can be accompanied by an increase in the resis
tance of the invertebrate to injurious conditions, like infec
tious disease, and a decrease in mortality. The composition
can be administered as granules or combined with a food
Source, Such as brine shrimp, in a Single or a plurality of
65 applications until treatment is completed.
The method can also include administering the Stimulat
ing agents of the present invention along with known
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antiviral, antibacterial or antifungal agents. Suitable anti
bacterial agents include penicillins, cephalosporins,
Vancomycin, bacitracin, and other antibiotics. Suitable anti
Viral agents include Vidarabine, acyclovir, ribavirin, aman
tadine hydrochloride, interferons, and the like. Suitable
antifungal agents include nyStatin, gentamicin, miconazole,

22
to 100% of the invertebrate organisms dead, and preferably,
80% to 100% of the organisms dead, and most preferably,
95% to 100% of the organisms dead after administration of
the biopesticide composition.
In a preferred version, an invertebrate pest Species, like
Manducca Sexta, is sprayed in the field with a biopesticidal
composition containing about 50 tug/ml body weight of an
inhibitor of an eicosanoid biosynthetic enzyme in a carrier of
paraffin wax and Soybean lecithin. The biopesticide compo
sition is applied until about 95% of the invertebrate pest is

and the like.

In a preferred version, an orally active and longer-acting
analog of a prostaglandin is combined with a food Source
and administered to an aquaculture of a crustacean, like
penaeid shrimp. The composition can be administered upon
the first Signs of infectious disease or as a prophylactic
measure in a Single or in multiple applications.
Method for Controlling the Growth of Invertebrate Pests
The present invention also provides a method for con
trolling or eradicating the growth of invertebrate pests
involving administering an effective pesticidal amount of a
biopesticide composition until growth of the invertebrate
Species is effectively inhibited. The biopesticide composi
tion is composed of at least one biologically active agent
which inhibits eicosanoid-mediated immune responses and a
physiological compatible carrier. The choice of the biologi
cally active agent will depend on the habitat and type of the
invertebrate species. Suitable biologically active agents
include those which inhibit eicosanoid-mediated immune

killed.
The invention has been described with reference to vari
15

EXAMPLE 1.

Larval tobacco hornworms, Manduca Sexta, were reared
under standard culture conditions at 28 C. under 16-hour

light/8-hour dark photoperiod. Experiments used early fifth
instar prewandering larvae. Test larvae were injected with 50
tug of either the phospholipase A inhibitor dexamethasone

25

responses Sufficiently to result in an increase in mortality of
the invertebrate Species and can be determined by the
method of the invention.

An effective biopesticidal amount of the biologically
active agent depends on the type of invertebrate Species, the
Size of the invertebrate, the method of administration, and

the type of biologically active agent. An effective biopesti
cidal amount for the particular invertebrate species is pref
erably that amount of the biologically active inhibitor which
inhibits immune responses Sufficiently to result in a decrease
of at least about 2-fold in the percentage of invertebrate
organisms Surviving a pathogenic infection when compared
to control invertebrates. Suitable dosage ranges include

35

about 1x10 ug/gm body weight to 1x10 ug/gm body

weight, and more preferably, about 1x10 ug/gm body
weight to 1x10 ug/gm body weight, and most preferably,
about 1x10" lug/gm body weight to 1 lug/gm body weight.
The composition is administered by combining it with a
food or water Source and feeding it to the invertebrate
Species, by injection, or preferably by Spraying the compo

(11 B, 16C.)-9-fluoro-11, 17,21-trihydroxy-16
methylpregna-1,4-diene-3,20-dione, the cyclooxygenase
inhibitor indomethacin 1-(p-chlorobenzoyl)-5-methoxy-2methyl-3-indolyl-acetic acid, the 5- and 12-lipoxygenase
inhibitor esculetin (6,7-dihydroxycoumarin) the nonspecific
antioxidant maleic acid (cis-butenedioic acid), or a 1:1
combination of indomethacin and eSculletin in 5 ul ethanol.
Control larvae were injected with 5 ul of absolute ethanol.
Injections were made by inserting the needle of a Hamilton
701 Syringe dorsolaterally above the last two spiracles,
moving the needle into the hemocell parallel to the body
wall to avoid injuring the alimentary canal, then depressing
the plunger.
Three to 10 minutes after injection of inhibitors, larvae
were infected with the pathogen Serratia marcescens by

intrahemocoelic injection of about 5x10 bacterial cells in

40

10 ul of broth, on the opposite side in the manner described
above. After a 2.5 hour incubation at 30° C., 100 ul of
hemolymph was withdrawn from each insect. The
hemolymph was diluted and plated on Standard methods
agar. The plates were allowed to dry, inverted and then
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incubated at 30° C. for 36-40 hours. Red bacterial colonies

50

on each plate were then counted. In all bacterial recovery
experiments, each agar plate represented a hemolymph
sample withdrawn from individually identifiable larvae.
Bacteria were recovered from Significantly more larvae
treated with eicosanoid biosynthesis inhibitors than from

Sition onto the invertebrate and/or its food or water Source.

The composition can be administered as a liquid, powder,
granules, or encapsulated like, for example, in lipoSomes.
The composition may be sprayed onto plant leaves and
foliage or water Sources by a low-pressure backpack Sprayer,
or by aerial Spraying. The composition is delivered to the
target invertebrate Species by ingestion, including ingestion
of a food or water Source containing the biologically active
agent, by penetration through the Outer Surface of the
invertebrate body including wound penetration, and by
injection. The composition can also be delivered by geneti
cally engineering microorganism which, as it grows in the
invertebrate Species, expresses, Secretes and delivers the
biologically active agent. The composition can be adminis
tered at all Stages if the life cycle of the invertebrate Species,
but is preferably administered to the larval Stage.
The biopesticidal composition is administered in a single
or a plurality of applications until the growth of the inver
tebrate species is effectively inhibited. Inhibition of growth
of the invertebrate Species is determined by the percentage
of invertebrate Surviving after the administration of the
composition. An effective inhibition of growth is about 50%

ouS Specific and preferred embodiments and techniques,
however, it should be understood that many variations and
modifications may be made while remaining within the Spirit
and Scope of the invention.

controllarvae. S. marceScenS bacterial colonies were Seen on

55

87% of the plates from dexamethasone treated larvae,
whereas only 21% of the plates from control larvae had
visible colonies. Larvae treated with compounds that block
only one of the two main polyunsaturated fatty acid oxy
genation pathways yielded intermediate results: colonies
were recovered from about 58% of the esculetin-treated

larvae, and from about 55% of the indomethacin-treated
60

65

larvae. When both major pathways were inhibited simulta
neously with indomethacin and esculetin, bacterial colonies
were recovered from 86% of the larvae, which is nearly
identical to the dexamethasone effect. Experiments with a
nonspecific anti-oxidant compound maleic acid, which does
not inhibit polyunsaturated fatty acid oxygenation pathways,
yielded results identical to those of control larvae. Inhibition
of eicosanoid formation with Specific inhibitors of phospho
lipase A2, cyclooxygenase and lipoxygenase significantly
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ethasone plus 50 lug of arachidonic acid. Control larvae
received 5 ul of absolute ethanol. The larvae were then

23
reduces the ability of larvae to clear pathogenic bacteria
from their hemolymph. Inhibitors of eicosanoid biosynthesis
inhibit the invertebrate immune response to bacterial infec

intrahemocoelically infected with 6x10 cells of the bacteria

tions.
5

EXAMPLE 2

doses of dexamethasone, ethanol, the cell free bacterial

culture broth and arachidonic acid. In all cases unchallenged
larvae Survived during the 24 hour experimental period and

Larval tobacco hornworms, M. Sexta, were reared as

described in Example 1. Larva were intrahemocoelically
injected with 50 lug of dexamethasone, a phospholipase A
inhibitor, in 5 ul absolute ethanol. Three to ten minutes after
injection of the inhibitors, larvae were infected with S.

showed no adverse behavioral effects.
The results of dexamethasone treatment on larval Survival
show that an increase in the dose of the inhibitor resulted in

an increase in the mortality of the invertebrate species. At 14
hours post-infection, 46.3% of the ethanol treated control

marcescens by intrahemocoelic injection of about 5x10

bacterial cells in 10 ul of broth, on the opposite side. Control
larvae were injected with 5 ul of absolute ethanol and then
similarly infected with bacteria. At 15 minutes intervals
post-infection, 15 ul of hemolymph Samples were Serially
withdrawn from the caudal horn, diluted and plated onto
Standard methods agar plates, and incubated for 36-40
hours. Bacterial colonies on each plate were then counted.
Within one hour post-infection, the dexamethasone
treated hornworms showed an increased in bacterial growth.

larvae, and 43.9% of the larvae treated with the low dose of

15

(CFU) of bacteria per ml of hemolymph were detected, and

doubled to 3.3x10 CFU/ml. By 60 minutes post-infection,

larvae treated with both dexamethasone and arachidonic
25

bacteria in the dexamethasone-treated worms was increased

2.5 times that of the level of bacteria at 15 minutes post
infection. In contrast, bacteria recovery from control horn

and no increase in growth of the bacteria was detected.
These results indicate that inhibition of eicosanoid biosyn
thesis allowed bacterial growth to begin early in the
hemolymph and inhibited early immune responses.
35

After a 1-hour incubation at 30° C., 100 ul of hemolymph
was withdrawn from each insect as described in Example 1.
The hemolymph was placed in 10 ml of dilution broth and
0.1 ml was plated in duplicate on Standard methods agar. The
plates were incubated, and bacterial colonies were counted
as described in Example 1.
Hemolymph samples from larvae treated with ethanol or

40
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with a lower dose of 1.4x10 ug of dexamethasone per

larvae had a very low level of bacterial infection with

0.35x10' CFU for the control and 0.55x10' CFU for the

50

1.4x10 ug of dexamethasone-treated larvae. Larvae
treated with higher doses of 1.4x10 ug or 1.4x10' lug of
dexamethasone had significantly increased levels of bacte
rial growth with 8.2x10 CFU and 10.1x10 CFU/ml of

hemolymph, respectively. Other experiments with higher
dosages of dexamethasone did not further increase recovery
of bacterial colonies. Dexamethasone treatment compro
mised the ability of hornworm larvae to clear S. marceScens
from hemolymph in a dose-responsive manner. AS the dose
of the inhibitor increased, an increase in bacterial growth
was observed indicating an inhibition of the immune
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M. Sexta larvae were also injected with 0.14 ug of dexam

saturated fatty acids were composed of 20%, 20:3 (n-6),
34% 20:4 (n-6) and 46% 20:5 (n-3). Retention times and

mass Spectra of these compounds were exactly congruent
with authentic Standards. Thus, all potential eicosanoid
precursors were present in Sufficient quantities to Support
eicosanoid biosynthesis.

Fifth instar M. sexta larvae were injected with 9.25x10
Bq of tritiated arachidonic acid (5,6,8,9,11,12,14,15-H)
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EXAMPLE 4

M. sexta larvae were injected with 1.4x10, 1.4x10 or

Total lipids were extracted from hemolymph and fat
bodies from five fifth-instar larvae. Phospholipids were
further isolated by thin-layer chromatography of the total
lipid extract. Purified phospholipids were transmethylated
by refluxing in acidified methanol for 1 hour at 85 C.
Resulting fatty acid methyl esters were analyzed by gas
chromatography and mass Spectrometry.
Analysis of the fatty acid compositions of phospholipids
purified from hemolymph M. Sexta larvae showed that all
three eicosanoid precursor polyunsaturated fatty acids were
present. These three components accounted for about 1% of
the total phospholipid fatty acids, comparable to results from
many other terrestrial insect species. The precursor polyun

EXAMPLE 6

response.

1.4x10' lug of dexamethasone per larvae, as in Example 3.

Synthesis compromise the ability of the larvae to clear
bacteria from circulation and increase mortality in the first
24 hours post-infection. This effect is reversed by the
presence of arachidonic acid indicating that eicosanoids
mediate important early steps in the immune response which
affect the survivability of the organism.
EXAMPLE 5

M. Sexta larvae were intrahemocoelically injected with
ethanol, or with different dosages of dexamethasone, includ

ing 1.4x10 or 1.4x10 or 1.4x10 ug of dexamethasone
per larvae, and then infected with 6x10 of S. marcescens.

acid were alive when compared with 46.3% of the ethanol
treated control larvae. In contrast, only 9.8% of the larvae
treated with 0.14 ug of dexamethasone alone Survived. Thus,
dexamethasone and the other inhibitors of eicosanoid bio

worms was below 10 CFU for the first hour post-infection

EXAMPLE 3

1.4x10 ug of dexamethasone per larvae were alive. Larvae
treated with higher doses of 1.4x10' ug or 1.4x10 ug of
dexamethasone only 9.8% and 24.4% of the larvae were
alive, respectively.
The higher concentrations of dexamethasone greatly
reduced the proportion of larvae that Survived pathogen S.
marceScenS infection. The effect of the higher concentra
tions of dexamethasone was reversed by treatment with
arachidonic acid. At 14 hours post-infection, 45% of the

At 15 minutes post-infection, 1.8x10" colony forming units
by 45 minutes post-infection, that number had nearly

S. marcescens. After 14 hours at 30° C., Surviving larvae
were counted. Unchallenged larvae were injected with large
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20:4; 2.22–3.70 TBq/mmol). After 1 minute, 100 ul of

hemolymph was collected as described in Example 1.
Eicosanoids were extracted three times with acidified ethyl
acetate and then Separated by thin-layer chromatography.
Fractions were identified by cochromatography with authen
tic unlabeled Standards and radioactivity in each fraction
was assayed by liquid Scintillation counting on a LKB
Wallac 1219 Rackbeta counter at 66% counting efficiency.
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One minute after injection, 100 ul of hemolymph Samples
were withdrawn from each of Seven larvae. In these samples,

acid, Salicylic acid acetate, neomycins, benzoxazoleacetic
acids, and dihydroxyanthrones.
3. A method of claim 1, wherein the biologically active
agent is Selected from the group consisting of EbSelen

5.3% of the injected radioactivity (mean=2.9x10 DPM)

was recovered. Most (95 to 97%) of the recovered radioac

(2-phenyl-1,2-benzisoselenazol-3(2H)-one), REV-5901 (23(1-hydroxy hexyl)phenoxy methylquinoline
hydrochloride), REV-5901 paraisomer, cinnamyl-3,4dihydroxyl-a-cyano-cinnamate (CDC), Baicalein (5,6,7trihydroxyflavone), caffeic acid, curcumin, CDP-choline,
5,6-dehydro-arachidonic acid, dexamethasone, DEDA (7,7dimethyl-eicosadienoic acid), dipyridamole, ETYA (5,8,11,
14-eicosatetraynoic acid), ETI (5,8,11-eicosatriynoic acid),

tivity was arachidonic acid. Three fractions had chromato
graphic behavior identical to the prostaglandins PGFC,
each PGE and PGD. A similar amount of radioactivity was
also recovered in an otherwise uncharacterized fraction in

the R range reported for lipoxygenase metabolites in mam
malian Systems, presumably hydroxyeicosatetraenoic acids.

Thus, larvae of M. Sexta were able to convert radioactive
arachidonic acid into eicosanoids.

eSculletin, gossypol, indomethacin, 5,6-methanoleukotriene

EXAMPLE 7

Healthy penaeid shrimp held in aquaculture tanks are
injected with either 1 ug/gm body weight of PGE, PGF2,
PGD, arachidonic acid, hydroxyeicosatetraenoic acid,

15

A methyl ester, naproxen, NDGA (nordihydroguaiaretic
acid), oleyloxyethyl phosphorylcholine, phenidone, chlor
promazine HCl, manoalide, nifedipine, aminocephalospo
ranic acid, aristolochic acid, Compound 48/80, neomycin

15(R)-15 methyl-PGE2 (a PGE analog) or d1-(11R,15RS)11, 15-dehydroxy-15-methyl-9-oxo-13-thioprostanoic acid,
p-benzamidophenyl ester (a prostaglandin analog) in phos

Sulfate, aspirin, benoxaprofen, AA-861 (2-(12-hydroxy-5,
10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone),

phate buffered saline. The shrimp are then injected with
two-fold dilutions of Vibrio parahemaelyticus biotype algi
nolyticus or Vibrio anquillarum and observed for the devel
opment of clinical Signs of bacterial infection and Subse
quent mortality. Clinical Signs of bacterial infection include
lethargy, white discoloration of abdominal musculature,
dorsal flexure of the abdomen, redness of periopods and
pleopods. The ability of prostaglandins and prostaglandin
analogs to protect the shrimp from fatal bacteremia is
examined. Protection of the shrimp from fetal bacteremia by
treatment with a prostaglandin or its analogs is likely.

cyclooxygenase inhibitors, 5-lipoxygenase inhibitors,
12-lipoxygenase inhibitors, and phospholipase inhibitors.
4. A method of claim 1, wherein the biologically active
agent is Selected from the group consisting of 13-APA

nafazatrom, quericetrin, REV-5367, REV-5741, REV-5747,
REV-5827, REV-5875, REV-5965, REV-6080, anthralin,
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(13-azaprostanoic acid), carbacyclin, CTA (carbocyclic
thromboxane A2), U-44069 (9,11-dideoxy-11-C-9-C.epoxymethanoprostaglandin F2O), U-46619 ((15S)-15
hydroxy-11-C-9-O-(epoxymethano)prosta-5(Z), 13(E)dienoic acid), DSCG (cromolyn), Oxatomide, PTA, (pinane
thromboxane A2), and Xanthines.
5. A method according to claim 1, wherein the composi
tion further comprises a Surface active agent.

EXAMPLE 8

Anopheles larvae are treated with dexamethasone or
dexamethasone and eSculletin and/or the Bacillus thurigien
Sis Serotype H-14. For field application against floodwater
mosquitos, 500 grams of Bacillus thurigiensis wettable
powder is suspended in 10 liters of phosphate buffered saline
or phosphate buffered Saline with 1 mg/ml dexamethasone
or phosphate buffered Saline with 1 mg/ml of dexametha
Sone and eSculletin. The mixture is applied by pressurized
SprayerS on one ha of water Surface. Some areas are treated
with 1 mg/ml of dexamethasone in phosphate buffered Saline
alone or 1 mg/ml dexamethasone and 1 mg/ml esculetin of
phosphate buffered saline. The effect of inhibitors of
eicosanoid biosynthesis on mosquito growth is observed in
the presence and absence of a known bio-control agent
Bacillus thurigiensis Serotype H-14. An increase in mortality
associated with the infection of Bacillus thurigiensis in the
presence of inhibitors of eicosanoid biosynthesis is likely.
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What is claimed is:

1. A method of altering a cellular immune response of an
arthropod comprising: administering a pharmaceutical com
position to an arthropod in an effective amount to inhibit an
eicosanoid-mediated cellular immune response of the
arthropod, the composition comprising a biologically active
agent which is effective to inhibit eicosanoid-mediated cel
lular immune responses of the arthropod and a physiologi
cally acceptable carrier.
2. A method of claim 1, wherein the biologically active
agent is an eicosanoid biosynthesis inhibitor Selected from
the group consisting of cinnamic acid, glucocorticoids,
dihydroxybenzopyran ketones, methanoleukotrienes,
b in aphthale ne S, naphthale ne acetic acids,
phosphorylcholines, indole acetic acids, dihydropyridine
carboxylic acids, phenanthrene carboxylic acids, Salicylic
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6. A method according to claim 1, wherein administering
the composition comprises Spraying the composition onto
the arthropod.
7. A method according to claim 1, wherein administering
the composition comprises injecting the composition into
the arthropod.
8. A method according to claim 1, wherein administering
the composition comprises feeding the composition to the
arthropod.
9. A method of decreasing cellular immunity of an arthro
pod to disease, comprising administering to the arthropod a
biopesticide composition in an effective amount to decrease
a cellular immune response, the composition comprising a
biologically active agent which inhibits eicosanoid
mediated cellular immune responses and a physiologically
acceptable carrier.
10. A method of claim 9, wherein the biologically active
agent is Selected from the group consisting of cinnamic
acid, glucocorticoids, dihydroxybenzopyran ketones,
methanoleukotrienes, binaphthalenes, naphthalene acetic
acids, phosphorylcholines, indole acetic acids, dihydropyri
dine carboxylic acids, phenanthrene carboxylic acids, Sali
cylic acid, Salicylic acid acetate, neomycins, benzox
aZOleacetic acids, and dihydroxyanthrones.
11. A method of claim 9, wherein the biologically active
agent is Selected from the group consisting of EbSelen

(2-phenyl-1,2-benzisoselenazol-3(2H)-one), REV-5901 (23(1-hydroxy hexyl)phenoxy methylquinoline
hydrochloride), REV-5901 paraisomer, cinnamyl-3,4dihydroxyl-a-cyano-cinnamate (CDC), Baicalein (5,6,7trihydroxyflavone), caffeic acid, curcumin, CDP-choline,
5,6-dehydro-arachidonic acid, dexamethasone, DEDA (7,7dimethyl-eicosadienoic acid), dipyridamole, ETYA (5,8,11,
14-eicosatetraynoic acid), ETI (5,8,11-eicosatriynoic acid),
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eSculletin, gossypol, indomethacin, 5,6-methanoleukotriene

12. A method of claim 9, wherein the biologically active
agent is Selected from the group consisting of 13-APA

A methyl ester, naproxen, NDGA (nordihydroguaiaretic
acid), oleyloxyethyl phosphorylcholine, phenidone, chlor
promazine HCl, manoalide, nifedipine, aminocephalospo
ranic acid, aristolochic acid, Compound 48/80, neomycin

Sulfate, aspirin, benoxaprofen, AA-861 (2-(12-hydroxy-5,
10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone),

nafazatrom, quericetrin, REV-5367, REV-5741, REV-5747,
REV-5827, REV-5875, REV-5965, REV-6080, anthralin,

cyclooxygenase inhibitors, 5-lipoxygenase inhibitors,
12-lipoxygenase inhibitors, and phospholipase inhibitors.

5

(13-azaprostanoic acid), carbacyclin, CTA (carbocyclic
thromboxane A2), U-44069 (9,11-dideoxy-11-C-9-C.epoxymethanoprostaglandin F2O), U-46619 ((15S)-15
hydroxy-11-C-9-O-(epoxymethano)prosta-5(Z), 13(E)dienoic acid), DSCG (cromolyn), Oxatomide, PTA, (pinane
thromboxane A2), and Xanthines.
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